ARTHUR BEAUDET, MD
Medical Practice at Fannin St, Houston, TX

2010013, Jun 3, 2010

Aug 31, 2009

12/551313

Arthur Beaudet - Houston TX, US
Shay Ben-Shachar - , US
Trilochan Sahoo - , US

C12Q 1/68

435 6

The present invention concerns genetic marker for adverse behavioral conditions. In particular aspects, the marker is present at chromosome 15q13 and comprises CHRNA7. In certain cases, the marker is a microdeletion or point mutation in CHRNA7.

6818401, Nov 16, 2004

Oct 2, 2001

09/969861

Arthur Beaudet - Houston TX
Olaf Bodamer - Vienna, AT
Ann Killary - Houston TX
Maria Mercedes Lovell - Houston TX

Board of Regents University of Texas System - Houston TX
Baylor College of Medicine - Houston TX

C12Q 168

435 6, 435325, 435455, 435461

The present invention relates to a method for detection and interpretation of loss-of-function or gain-of-function mutations for test genes of interest. The genes of interest include those associated with inherited genetic disorders. The present invention involves the process of obtaining a sample of genetic material from an individual in the form of tissue or cells, separation of the genetic material from the cells of the individuals into haploid sets by transferring the individual chromosomal entities into a population of target cells, and monitoring the target cell population for successful transfer and expression of the test genes of interest using various functional, immunological and structural assays.

5681699, Oct 28, 1997

Feb 11, 1994

8/196003

Jerome I. Rotter - Los Angeles CA
Stephan R. Targan - Los Angeles CA
Huiying Yang - Cerritos CA
Arthur L. Beaudet - Houston TX
Devendra Vora - Torrance CA

Cedars-Sinai Medical Center - Los Angeles CA

C12Q 168, C07H 2102, C07H 2104

435 6

A novel association between IBD and a polymorphism at amino acid residue 241 of ICAM-1 has been discovered. In accordance with the present invention there is provided methods of screening for IBD, methods for treating IBD, antibodies specifically reactive wish ICAM-1 encoded by R241 allele and kits which exploit the inventive methods.

6008335, Dec 28, 1999

Sep 19, 1997

8/933824

Jerome I. Rotter - Los Angeles CA
Stephan R. Targan - Los Angeles CA
Huiying Yang - Cerritos CA
Arthur L. Beaudet - Houston TX
Devendra Vora - Torrance CA

Cedars-Sinai Medical Center - Los Angeles CA

C07H 2102, C07H 2104, C12Q 168

536 231

A novel association between IBD and a polymorphism at amino acid residue 241 of ICAM-1 has been discovered. In accordance with the present invention there is provided methods of screening for IBD, methods for treating IBD, antibodies specifically reactive with ICAM-1 encoded by R241 allele and kits which exploit the inventive methods.

6884590, Apr 26, 2005

Oct 15, 1999

09/419408

Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Arthur L. Beaudet - Houston TX, US
Devendra Vora - Torrance CA, US

Cedars-Sinai Medical Center - Los Angeles CA

G01N033/53

435 71, 435 6, 435 72, 5303871, 536 235

A novel association between IBD and a polymorphism at amino acid residue 241 of ICAM-1 has been discovered. In accordance with the present invention there is provided methods of screening for IBD, methods for treating IBD, antibodies specifically reactive with ICAM-1 encoded by, R241 allele and kits which exploit the inventive methods.

5602307, Feb 11, 1997

Sep 20, 1994

8/309549

Arthur L. Beaudet - Houston TX
Raymond Wilson - Timonium MD
Allan Bradley - Houston TX
William E. O'Brien - Houston TX
James Sligh - Houston TX
Christie Ballantyne - Houston TX
Daniel Bullard - Houston TX

Baylor College of Medicine - Houston TX

C12N 1500, C12N 500, A61K 4900

800 2

A transgenic mouse which contains a predefined, specific and desired alteration in at least one of its two chromosomal alleles of a cellular adhesion gene, such that at least one of these alleles contains a mutation which alters the expression of the allele.

2013000, Jan 3, 2013

Jun 18, 2012

13/525677

Arthur L. Beaudet - Houston TX, US
Frederic M. Vaz - Amsterdam, NL

A61K 31/205, A61P 25/00, A61K 31/221

514546, 514556

Embodiments of the invention include determining whether an individual has autism spectrum disorder or is at risk for developing autism spectrum disorder or at risk for regression of or into autism spectrum disorder. Specific embodiments include the determination of indicative levels of carnitine or other metabolites in carnitine biosynthesis and may include assaying for mutations in TMLHE, including in exon 2, for example. In some cases one can assay for mutations in TMLHE in the absence of biochemical analysis of carnitine biosynthesis metabolites. An individual with deficiency in TMLHE and/or carnitine levels may be administered carnitine, acetylcarnitine, butyrobetaine, or a combination thereof, for example.